GWS
CSTL icon

Glassman Wealth Services’s Castle Biosciences CSTL Stock Holding History

Glassman Wealth Services’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-23
Closed -$1K – 1729
2022
Q1 		$1K Buy
+23
New +$950 ﹤0.01% 1366
2020
Q1 		– Sell
-9
Closed – – 1205
2019
Q4 		$0 Buy
+9
New +$220 ﹤0.01% 1225

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Glassman Wealth Services's CSTL Position: Q2 2022 in Review

Glassman Wealth Services sold out of Castle Biosciences (CSTL) in Q2 2022, closing a stake of 23 shares — an estimated $1K sold.

Glassman Wealth Services first reported a position in CSTL in Q4 2019 and held it in 2 quarters. The position peaked at $1K in Q1 2022. 146 funds tracked by Wall St. Rank hold CSTL as of Q2 2022.

  • Glassman Wealth Services reported no remaining Castle Biosciences position as of Q2 2022 after selling out during the quarter.
  • Glassman Wealth Services sold 23 Castle Biosciences shares in Q2 2022, an estimated $1K.
  • Glassman Wealth Services first reported a position in Castle Biosciences in Q4 2019 and held it in 2 quarters.
  • Glassman Wealth Services's Castle Biosciences position peaked at $1K in Q1 2022.
  • 146 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2022.

Based on Glassman Wealth Services's 13F filing for Q2 2022, filed 4 Aug 2022.